Literature DB >> 31316643

Organophosphorus-Induced Toxic Myeloneuropathy: Series of Three Adolescent Patients with Short Review.

Priyabrata Nayak1, Ashok K Mallick1, Shubhankar Mishra1, Debasish Panigrahy1.   

Abstract

Organophosphate (OP) poisoning is the most common poisoning in India, accounting for almost half of the hospital admissions due to poisoning. Delayed neuropathy is initiated by an attack on a nervous tissue esterase. Although uncommon, delayed neurotoxicity has been consistently reported in literature. This mechanism is implicated not only in damaging peripheral nervous system but also in causing central processes leading to myelopathy. We report a series of three adolescent patients who came to our hospital with delayed neurological manifestations of organophosphorus poisoning, which came out to be OP-induced myeloneuropathy after detailed analysis and evaluation.

Entities:  

Keywords:  Myeloneuropathy; OPIDN; nerve conduction velocity; organophosphorus

Year:  2019        PMID: 31316643      PMCID: PMC6601111          DOI: 10.4103/jpn.JPN_45_18

Source DB:  PubMed          Journal:  J Pediatr Neurosci        ISSN: 1817-1745


INTRODUCTION

Organophosphate (OP) poisoning is known to cause varied neurological presentations in the form of acute, intermediate, and delayed neuropathy.[1] Many organophosphorus esters cause acute cholinergic neurotoxicity. Some of these compounds are capable of producing organophosphorus ester–induced delayed neurotoxicity.[2] Chlorpyrifos (O,O-diethyl O-3,5,6-trichloro-2-pyridylphosphorothioate) is known to cause a delayed syndrome or type III syndrome also called Organophosphorus-induced delayed neuropathy (OPIDN). It occurs especially in instances of high-dose exposure and in instances in which therapeutic agents were used to resolve acute cholinergic toxicity. The pathology involves a central-peripheral distal axonopathy. This is caused by a Wallerian-type degeneration of the axon, followed by myelin degeneration of long and large-diameter tracts of the peripheral and central nervous systems.[3] The prevalence of OPIDN is variable; however, it occurred in 22% of patients with OP poisoning in a recent study.[4] OPIDN occurs within a period of 1 week to 5–6 months of the ingestion of an OP compound, almost exclusively in patients with preceding acute cholinergic toxicity related to severe acute exposure (to an OP compound). But as the incidence of myeloneuropathy is very rare in OP poisoning, exact incidence is not known.

Case analysis

Details about case analysis are given in Table 1.
Table 1

Case history

CharacteristicsCase 1Case 2Case 3
Short nameS.D.S.B.A.N.
Age (years)181514
SexMFF
OccupationFarmerStudentStudent
Time of poisoning4 months2 months1 months
Chemical nameUnknownChlorpyrifosChlorpyrifos
PresentationUnable to walk without support—2 months Unable to stand up from sitting position—1 monthUnable to stand up from sitting position—15 days Unable to clear obstacles on ground while walking —10 daysTightness of both LL—10 days Numbness over both feet and hands—10 days
Examination findings– Diminished power in B/l LL (4/5-MRC Scale) – B/l spasticity in LL – Left side foot drop – DTR brisk in b/l knee. Diminished in b/l ankle – Plantar response extensor B/L – Pain, temperature loss below T6 by 60% – Vibration lost below ASIS– Diminished power in B/l LL (4/5-MRC Scale) – B/l spasticity in LL – B/l foot drop – DTR brisk in b/l knee – Plantar response extensor B/L – Pain, temperature loss below T10 by 40% – Vibration lost below ASIS– Diminished power in B/l LL (4+/5-MRC Scale) – B/l LL spasticity – DTR brisk in LL – Plantar response extensor B/L – Pain, temperature, vibration loss in glove- and-stocking pattern
Blood investigationsNormalNormalNormal
Imaging (MRI of spinal cord with contrast)Cord atrophy involving T3 and T4 spinal segments. No spinal canal stenosisNormalCord atrophy involving T9 and T10 spinal segments. No spinal canal stenosis
Electrophysiology– NCS—markedly reduced amplitude of CMAP with reduced motor nerve conduction velocity in both tibial and peroneal nerves of both lower limbs. – SNAP was normal in all peripheral nerves – EMG showed compatible (distal > proximal) symmetrical limb denervation changes with sparing of thoracic paraspinals– NCS— markedly reduced amplitude of CMAP with reduced motor nerve conduction velocity in peroneal nerves of both lower limbs – SNAP was normal in all peripheral nerves – EMG showed compatible (distal > proximal) symmetrical limb denervation changes with sparing of thoracic paraspinals– NCS— markedly reduced amplitude of CMAP with reduced motor nerve conduction velocity in tibial and peroneal nerves of both lower limbs – CMAP and motor nerve conduction velocity were mildly reduced in median and ulnar nerves – SNAP was decreased in all peripheral nerves. – EMG showed compatible (distal > proximal) symmetrical limb denervation changes with sparing of thoracic paraspinals
TreatmentInj methylcobalamin, physiotherapy, and occupational therapyInj methylprednisolone, Inj methylcobalamin, physiotherapy, and occupational therapyInj methylprednisolone, Inj methylcobalamin, physiotherapy, and occupational therapy
Follow-upMild improvement after 2 monthsSubjective improvement seen after 2 monthsMild improvement after 2 months

M = male, F = female, B/l = bilateral, L/L = lower limb, MRC = medical research council, DTR= deep tendon reflex, NCS = nerve conduction studies, CMAP = compound motor action potential, SNAP = sensory nerve action potential, EMG = electromyogram, MRI = magnetic resonance imaging

Case history M = male, F = female, B/l = bilateral, L/L = lower limb, MRC = medical research council, DTR= deep tendon reflex, NCS = nerve conduction studies, CMAP = compound motor action potential, SNAP = sensory nerve action potential, EMG = electromyogram, MRI = magnetic resonance imaging

DISCUSSION

OP and carbamates compounds are used for pest control. Adolescent age group is highly vulnerable for suicidal attempts due to increasing adaptation problems and emotional situations. Easy accessibility and cheap economical value make the OP and carbamates primary substance as suicidal agents. Three different types of neurological presentations have been recognized following OP poisoning. Type I paralysis or cholinergic crisis occurs due to excessive stimulation of muscarinic receptors by Ach due to blockade of acetylcholinesterase by an OP agent. Type II paralysis or intermediate syndrome is a distinct clinical entity having incidence of 8%–49% and it usually appears 24–96h after poisoning.[5] The pathogenesis is hypothesized to be the dysfunction of neuromuscular junction due to downregulation of both presynaptic and postsynaptic nicotinic receptors due to release of excessive Ach and Ca2+, respectively.[5] The cardinal clinical features comprise muscular weakness affecting predominantly the proximal muscles and neck flexors. Type III paralysis or OPIDN is a pure motor or predominantly motor axonal neuropathy characterized by wrist drop and foot drop with minimal or no sensory loss, which occurs 7–20 days after exposure to an OP agent.[6] Delayed organophosphorus ester-induced neurotoxicity (OPIDN) is further classified into four stages that consist of the latent period, progressive phase, stationary phase, and improvement phase.[2] Latent period: It is characterized by a delay in the onset of neurological deficits after exposure to OPs. The length of this latent period varies from 10 days to 3 weeks after exposure and depends on several factors such as nature of the chemical, the route of exposure, the dose size, duration and frequency of exposure, and individual variation in metabolism.[2] This phase was widely variable in our study. In the first case, it was 8 weeks. This is quite long according to reported literature. A lengthy “latent period” as in this case has been documented previously.[27] In the other two cases, latent period was 6 and 3 weeks, respectively. Progressive phase: In this phase, symptoms and signs progress rapidly and present with motor sensory polyneuropathy predominantly affecting the lower limbs. Sensory symptoms include both positive and negative sensory symptoms such as cramping, burning pain in the calves, numbness, and tingling in the extremities and limbs. Sensory symptoms include “glove-and-stocking” sensory loss and involvement of posterior column.[3] Motor signs are predominant and consist of bilateral foot drop, which may progress to flaccid paralysis involving all four limbs. Bladder and bowel involvement is though rare but evident in many cases. In our series, all the cases were having both motor and sensory involvements. Stationary phase: During this phase, bilateral paraplegia or quadriplegia persists. Case 1 patient in our study was in this phase. Other two cases were in late progressive and early stationary phase. That insisted us to treat by injection methylprednisolone. Improvement phase: During this phase, sensory symptoms disappear first followed by improvement in motor function in cranio-caudal manner. As improvement resulting from regeneration of the peripheral nervous system occurs, cord damage is unmasked, which manifests as spasticity with exaggerated reflexes. On follow-up, all our patients are in improvement phase with sequential improvement of sensory symptoms followed by motor symptoms. During follow-up, spasticity with the absence of lower motor signs was in keeping with the improvement phase, signifying rapid regeneration of the peripheral nerves. Myeloneuropathy in delayed OP poisoning is a predominant feature in chlorpyrifos poisoning like our two cases. One hypothesis involves neuropathy target esterase (NTE), an enzyme with unclear function in the brain, spinal cord, and the peripheral nervous system and is thought to be implicated in the pathophysiology of OPIDN. The axonopathy is thought to be attributed to the inhibition of NTE by phosphorylation and subsequent aging of NTE that involves cleavage of the lateral side chain from the phosphorylated NTE.[8] Chlorpyrifos is classified as “Moderately Hazardous (Class II)” as per the World Health Organization Organophosphorus Compound Classification. For OPIDN to occur, phosphorylated and cleaved NTE is necessary in significant amounts. In chlorpyrifos, the active metabolite has an anticholinesterase to anti-NTE ratio of 0.07.[3] Carbamates are only rarely associated with the development of OPIDN.[9] In all the three cases, myelopathy was the predominant picture than neuropathy. It is very rare but reported in some studies. A Sri Lankan study reported more than half of the 20 young girls who consumed OP compound presented with pyramidal signs during the latter part of the illness.[10] Some case reports were surfaced with this rare manifestation of OPIDN.[1112] Prognosis of OP-induced neurotoxicity depends on the degree of axonal degeneration.

CONCLUSION

OP poisoning is one of the most common hazards seen in Indian households. Delayed myeloneuropathy is one of the complications seen after stabilization in the acute phase. Early diagnosis and adequate therapy can help many young people to fight this irreversible morbidity. Precise reporting of such neurotoxicities of common household toxins may help us in gaining more insight into the mechanism to provide a better therapy in future. All neurophysicians must be aware of this rare complication for further studies to delineate better dimensions in neurotoxicology.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  2 in total

1.  Delayed myelopathy after organophosphate intoxication: A case report.

Authors:  Sandesh Gautam; Sanjaya Sapkota; Rajeev Ojha; Anamika Jha; Ragesh Karn; Bikram Prasad Gajurel; Reema Rajbhandari; Sunanda Paudel; Niraj Gautam; Ashish Shrestha
Journal:  SAGE Open Med Case Rep       Date:  2022-06-16

Review 2.  PNPLA6/NTE, an Evolutionary Conserved Phospholipase Linked to a Group of Complex Human Diseases.

Authors:  Doris Kretzschmar
Journal:  Metabolites       Date:  2022-03-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.